Institution of an Italian Multicenter Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism
NCT06645899 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600
Last updated 2025-01-23
Summary
The goal of this observational study is to create, manage and analyze a multicenter national database of patients affected by hypoparathyroidism or pseudohypoparathyroidism, aimed at collecting and studying anamnestic, diagnostic, genetic, clinical, and therapeutic data in a relatively wide number of patients with these two rare pathologies, in Italy.
The study will include 41 specialist clinical centers of endocrinology, pediatric endocrinology, pediatrics, and endocrine surgery, located throughout the Italian territory, and to which patients refer from all the 20 regions of Italy.
Data will be collected over time, both in retrospective and prospective manners, during the 10-year duration of the study, starting from the recruiting visit (basal visit) and then during each follow-up visits patients will undergo for the control of disease at the recruiting clinical centers.
Collected data will include both the most classic traits of the pathology and the less common ones, with the final goal of refining and deepening medical knowledge in the field of these two clinical conditions affecting parathyroid function and calcium homeostasis, and, thus, to be able to define optimal clinical and therapeutic management of patients, improving their quality of life.
The main aspects this observational study aims to assess and clarify are:
1. Evaluation of prevalence and incidence of hypoparathyroidism, globally and in its different etiological forms, and of pseudohypoparathyroidism in Italy.
2. Clinical characterization of different etiological forms of hypoparathyroidism, through both cross-sectional and longitudinal analyses of collected data.
3. Clinical characterization of pseudohypoparathyroidism, through both cross-sectional and longitudinal analyses of collected data.
4. Over time collection of data on bone status and bone fragility in patients with hypoparathyroidism and pseudohypoparathyroidism, to evaluate the prevalence and incidence of fragility fractures in these patients, globally and also based on gender, age, and disease etiology.
5. Over time evaluation of response to pharmacological therapies in patients with hypoparathyroidism and pseudohypoparathyroidism The study will include two independent cohorts of female and male patients of any age, one including patients with chronic hypoparathyroidism of each etiological forms (cohort 1), and one including patients with pseudohypoparathyroidism (cohort 2). The study does not include either any control group/comparison group or healthy volunteers.
The study itself does not involve any medical intervention or drug administration. Pharmacological treatments for which data on response to therapy will be collected in the database, are those administered to patients for the control/treatment of hypoparathyroidism or pseudohypoparathyroidism, regardless of their inclusion in this observational study.
Conditions
- Hypoparathyroidism
- Pseudo Hypoparathyroidism
Sponsors & Collaborators
-
F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-04
- Primary Completion
- 2034-11-04
- Completion
- 2034-11-04
Countries
- Italy
Study Locations
More Related Trials
-
Oral Peptones Load in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism and Healthy Subjects
NCT01042626 ·Status: COMPLETED ·Phase: NA
-
A Study for Teriparatide in Severe Osteoporosis
NCT00696644 ·Status: COMPLETED
-
Circulating Myokine Levels and Bone Metabolism
NCT04206618 ·Status: COMPLETED
-
Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism
NCT02417389 ·Status: COMPLETED ·Phase: PHASE4
-
Parathyroid Allotransplant for Treatment of Hypoparathyroidism
NCT06961071 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Effects of Genistein Aglycone in Glucocorticoid Induced Osteoporosis
NCT03040531 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Use of NPSP558 in the Treatment of Hypoparathyroidism
NCT00732615 ·Status: COMPLETED ·Phase: PHASE3
-
ADD-ON Study to Existing Hypoparathyroidism Studies
NCT00856401 ·Status: UNKNOWN ·Phase: PHASE3
-
PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
NCT00005005 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of PTH Replacement on Bone in Hypoparathyroidism
NCT00395538 ·Status: TERMINATED ·Phase: PHASE3
-
Denosumab vs Placebo in Patients With Thalassemia Major and Osteoporosis
NCT02559648 ·Status: COMPLETED ·Phase: PHASE2
-
Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
NCT00086619 ·Status: COMPLETED ·Phase: PHASE2
-
Parathyroid Hormone (PTH) With Alendronate for Osteoporosis
NCT00005006 ·Status: COMPLETED ·Phase: PHASE2
-
Bone Effects of Teriparatide Following Alendronate
NCT00191893 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of PTH(1-84) or Alendronate on Reduction of Back Pain in Postmenopausal Women With an Osteoporosis Related Vertebral Fracture(s) (FP-005-IM)
NCT00713258 ·Status: TERMINATED ·Phase: PHASE4
-
A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg/Day in Adult Participants With Hypoparathyroidism
NCT07081997 ·Status: RECRUITING ·Phase: PHASE3
-
Osteoporosis Treatment Protocol in Patients With Fragility Fractures: Application and Efficacy
NCT04861142 ·Status: UNKNOWN
-
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
NCT00051558 ·Status: COMPLETED ·Phase: PHASE3
-
Identifying Individuals at Risk of Glucocorticoid-Induced Impairment of Bone Disease
NCT06421597 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Prevention of Osteoporosis in Men With Prostate Cancer
NCT00048841 ·Status: COMPLETED ·Phase: PHASE3
-
One Week Comparison Study of PTH and PTHrP Infusions
NCT01333267 ·Status: WITHDRAWN ·Phase: PHASE1
-
Treatment of Low Bone Density in Cystic Fibrosis.
NCT01812551 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Investigate the Safety and Tolerability of NPSP558, for the Treatment of Adults With Hypoparathyroidism - A Clinical Extension Study in Hungary
NCT01455181 ·Status: COMPLETED ·Phase: PHASE3
-
Alendronate and/or Parathyroid Hormone for Osteoporosis
NCT00000400 ·Status: COMPLETED ·Phase: PHASE2
-
MAGnesium Effect With ANtiosteoporotic Drugs
NCT05328154 ·Status: COMPLETED ·Phase: PHASE2